Follow Us:
Nalidixic Exporter From India

Nalidixic

Nalidixic acid is a quinolone antibiotic historically used to treat urinary tract infections (UTIs) caused by susceptible Gram-negative bacteria, particularly certain strains of Escherichia coli, Proteus, and Klebsiella. It works by inhibiting bacterial DNA gyrase, an enzyme essential for DNA replication and bacterial growth. It was traditionally available as oral tablets or suspension, although its availability and clinical use are now limited in many countries because of bacterial resistance and the availability of newer antibiotics. Common side effects include nausea, vomiting, diarrhoea, abdominal discomfort, and headache. Serious risks may include seizures, photosensitivity, allergic reactions, and neurological adverse effects. Its use should follow current antimicrobial guidelines and medical advice, with susceptibility testing where appropriate.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Nalidixic

Nalidixic was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Nalidixic

Availability of Nalidixic

Delivery of Nalidixic

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Nalidixic.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Nalidixic.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nalidixic, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Nalidixic Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Nalidixic

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Nalidixic Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nalidixic, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Nalidixic

The export of Nalidixic from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Nalidixic Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Nalidixic specifications, certificates of analysis, and other supporting documents required for Nalidixic export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Nalidixic export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Nalidixic regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Nalidixic documentation, labelling, Nalidixic manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Nalidixic Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Nalidixic, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.